Pharmacy Cagrilintide monotherapy led to ~11.8% weight loss vs 2.3% with placebo over 68 weeks in the phase 3 REDEFINE 1 trial for adults with obesity or overweight plus comorbidities. Read more PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Cagrilintide 99%+ Pure Peptide Amino Club Amino Club Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library What is the pipeline for future medications for obesity? International Journal of Obesity Novo Nordisk presents phase 3 data for next generation amylin cagrilintide, leading to advancement into dedicated clinical programme